MAPT and Alzheimer disease: Recent studies using ultrasensitive immunoassays indicate that different pTau species (pT181, pT217 and pT231) in plasma samples perform very well to identify AD, and correlate with both Aβ and AD-type tau pathology as measured by PET [16, 20–22].